NEW YORK (GenomeWeb News) – Sequenom disclosed in a filing with the US Securities and Exchange Commission on Tuesday that it has reached a settlement with Ibis Biosciences in a patent infringement suit filed by Sequenom a year ago.

Under the agreement, Ibis will pay Sequenom $1 million within 30 days and the litigation will be dismissed. Under terms of the settlement agreement, Ibis and its parent company Abbott Laboratories will receive a non-exclusive license under three mass-spectrometry-based applications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.